

Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results

For Immediate Release

Richmond, TX (September 1, 2010) - A recent study conducted by oculoplastic surgeon Charles Soparkar, M.D., Ph.D. (The Methodist Hospital, Houston, TX) utilizing a patent-pending formulation of zinc and phytase (trademarked as ZYTAZE™), demonstrated that increasing zinc levels by oral administration for 4 days prior to a planned injection of botulinum toxin improved efficacy and/or duration in 41 of 44 patients tested (93%). Phytase was added to increase zinc absorption and significantly improved outcomes.



Charles Soparkar, M.D., Ph.D.

Oral supplementation of ZYTAZE™ prior to administration of botulinum toxin effectively increased responsiveness in virtually every individual tested. Many of these patients were considered to be poorly responsive to botulinum toxins such that control of their blepharospasm symptoms had been historically difficult to achieve. The results showed that ZYTAZE™ supplementation resulted in a remarkably effective treatment of blepharospasm using the same botulinum toxin source and dosage that was previously less effective in the same patient in the absence of supplementation.

Among other things, the results suggest that lowered doses of botulinum toxin could be administered with reasonable responsiveness in some patients if ZYTAZE™ is supplemented prior to treatment. Intake of zinc/phytase supplementation prior to administration provided increased responsiveness which can be normalized across the patient population and one important variable in individual responsiveness can be eliminated. Lower effective doses may reduce the subsequent development of antibodies that interfere with treatment.

Dr. Soparkar's research team will present the effect of dietary zinc supplementation on botulinum toxin treatments at the ASOPRS 41st Annual Fall Scientific Symposium on Thursday, October 14, 2010 at 8:05 AM in Chicago, IL.

For more information on ZYTAZE™ or to express interest in participation of the planned Scientific Advisory Board, visit OCuSOFT® Booth #526 at the 2010 American Academy of Ophthalmology (AAO) Joint Meeting in Chicago, IL.



Contact: Linda Dang
Phone: (281) 342-3350
Email: ldang@ocusoft.com

Finally, by supplementing with ZYTAZE™ prior to botulinum toxin injections, results for blepharospasm patients are enhanced while prolonging the duration of treatments.

ZYTAZE™ has been licensed to OCuSOFT, Inc., a company dedicated to ophthalmic research, development and patient care for nearly 25 years. To eliminate the potential for patient abuse and resulting zinc toxicity, ZYTAZE™ will be marketed as a prescription (Rx) when commercially available in September 2010. ZYTAZE™ will be packaged in a blister pack of ten tablets ensuring both its Rx designation and the quantity of tablets so that physicians will remain in control at all times.